Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase

被引:49
作者
Louis, JM [1 ]
Oroszlan, S
Tözsér, J
机构
[1] NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA
[2] Debrecen Univ Med, Sch Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary
[3] NCI, Mol Virol & Carcinogenesis Lab, ABL, Basic Res Program,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA
关键词
D O I
10.1074/jbc.274.10.6660
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have developed a system for expression and purification of wild-type human T-cell leukemia virus type 1 (HTLV-1) proteinase to attain sufficient quantities for structural, kinetic, and biophysical investigations. However, similar to the human immunodeficiency virus type 1 (HIV-1) proteinase, HTLV-1 proteinase also undergoes autoproteolysis rapidly upon renaturation to produce two products. The site of this autoproteolytic cleavage was mapped, and a resistant HTLV-1 proteinase construct (L40I) as well as another construct, wherein the two cysteine residues were exchanged to alanines, were expressed and purified. Oligopeptide substrates representing the naturally occurring cleavage sites in HTLV-1 were good substrates of the HTLV-1 proteinase. The kinetic parameters k(cat) and K-m were nearly identical for all the three enzymes. Although three of four peptides representing HTLV-1 proteinase cleavage sites were fairly good substrates of HIV-1 proteinase, only two of nine peptides representing HIV-1 proteinase cleavage sites were hydrolyzed by the HTLV-1 proteinase, suggesting substantial differences in the specificity of the two enzymes. The large difference in the specificity of the two enzymes was also demonstrated by inhibition studies. Of the several. inhibitors of HIV-1 or other retroviral proteinases that were tested on HTLV-1 proteinase, only two inhibit the enzyme with a K-i lower than 100 nM.
引用
收藏
页码:6660 / 6666
页数:7
相关论文
共 50 条
[1]   HIV-1 PROTEINASE IS REQUIRED FOR SYNTHESIS OF PRO-VIRAL DNA [J].
BABOONIAN, C ;
DALGLEISH, A ;
BOUNTIFF, L ;
GROSS, J ;
OROSZLAN, S ;
RICKETT, G ;
SMITHBURCHNELL, C ;
TROKE, P ;
MERSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 179 (01) :17-24
[2]   COMPLEX SPLICING IN THE HUMAN T-CELL LEUKEMIA-VIRUS (HTLV) FAMILY OF RETROVIRUSES - NOVEL MESSENGER-RNAS AND PROTEINS PRODUCED BY HTLV TYPE-I [J].
CIMINALE, V ;
PAVLAKIS, GN ;
DERSE, D ;
CUNNINGHAM, CP ;
FELBER, BK .
JOURNAL OF VIROLOGY, 1992, 66 (03) :1737-1745
[3]   ANALYSIS OF SUBSTRATE CLEAVAGE BY RECOMBINANT PROTEASE OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 REVEALS PREFERENCES AND SPECIFICITY OF BINDING [J].
DAENKE, S ;
SCHRAMM, HJ ;
BANGHAM, CRM .
JOURNAL OF GENERAL VIROLOGY, 1994, 75 :2233-2239
[4]   Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease [J].
Ding, YS ;
Owen, SM ;
Lal, RB ;
Ikeda, RA .
JOURNAL OF VIROLOGY, 1998, 72 (04) :3383-3386
[5]   THE DETERMINATION OF ENZYME INHIBITOR CONSTANTS [J].
DIXON, M .
BIOCHEMICAL JOURNAL, 1953, 55 (01) :170-171
[6]  
DUNN BM, 1994, METHOD ENZYMOL, V241, P254
[7]   HIV-protease inhibitors [J].
Flexner, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1281-1292
[8]  
GESSAIN A, 1985, LANCET, V2, P407
[9]   SELECTIVE PHOSPHINATE TRANSITION-STATE ANALOG INHIBITORS OF THE PROTEASE OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].
GROBELNY, D ;
WONDRAK, EM ;
GALARDY, RE ;
OROSZLAN, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 169 (03) :1111-1116
[10]  
GUSTCHINA A, 1995, PROTEIN SCI, V8, P1453